Treatment trends for retinopathy of prematurity in the UK: active surveillance study of infants at risk by Adams, GGW et al.
Treatment trends for retinopathy
of prematurity in the UK: active
surveillance study of infants at risk
Gillian G W Adams,1 Catey Bunce,1 Wen Xing,1 Lucilla Butler,2 Vernon Long,3
Aravind Reddy,4 Annegret H Dahlmann-Noor1
To cite: Adams GGW,
Bunce C, Xing W, et al.
Treatment trends for
retinopathy of prematurity in
the UK: active surveillance
study of infants at risk. BMJ
Open 2017;7:e013366.
doi:10.1136/bmjopen-2016-
013366
▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2016-013366).
Received 7 July 2016
Revised 9 November 2016
Accepted 11 January 2017
For numbered affiliations see
end of article.
Correspondence to
Dr Annegret Dahlmann-Noor;
annegret.dahlmann-noor@
moorfields.nhs.uk
ABSTRACT
Objectives: To estimate the incidence of severe
retinopathy of prematurity (ROP) requiring treatment
and describe current treatment patterns in the UK.
Design: Nationwide population-based case
ascertainment study via the British Ophthalmic
Surveillance Unit and a national collaborative ROP
special interest group. Practitioners completed a
standardised case report form (CRF).
Setting: All paediatric ophthalmologists providing
screening and/or treatment for retinopathy in the UK
were invited to take part.
Participants: Any baby with ROP treated or referred
for treatment between 1 December 2013 and 30
November 2014, treated with laser, cryotherapy,
vascular endothelial growth factor (VEGF) inhibitor or
vitrectomy/scleral buckling, or a combination.
Main outcome measure: Incidence of ROP
requiring treatment.
Results: We received 370 CRFs; 327 were included.
Denominator from epidemiological data: 8112 infants
with birth weight of <1500 g. The incidence of ROP
requiring treatment was 4% (327/8112, 95% CI 3.6% to
4.5%). Median gestational age was 25 weeks (IQR 24.3–
26.1), and median birth weight 706 g (IQR 620–821).
Median age at first treatment was 80 days (IQR 71–96).
204 right eyes (62.39%) had type 1 ROP, and 27
(8.26%) had aggressive posterior ROP. Infants were also
treated for milder disease: 9 (2.75%) right eyes were
treated for type 2 ROP, and 74 (22.63%) for disease
milder than type 1 with plus or preplus, which we
defined here as ‘type 2 plus’ disease. First-line treatment
was diode laser photoablation of the avascular retina in
90.5% and injection of VEGF inhibitor in 8%.
Conclusions: ROP treatment incidence in the UK is 2.5
times higher than previously estimated. 8% of treated
infants receive intravitreal VEGF inhibitor, currently
unlicensed. Research is needed urgently to establish
safety and efficacy of this approach. Earlier treatment and
increasing numbers of surviving premature infants require
an increase in appropriate eye care facilities and staff.
Trial registration number: NCT02484989.
INTRODUCTION
Retinopathy of prematurity (ROP) is a poten-
tially blinding condition typically affecting
preterm neonates of low gestational age and
low birth weight.1 ROP is a major cause of
preventable blindness in children worldwide:
of 15 million children born worldwide in
2010, an estimated 53 000 developed sight-
threatening type ROP requiring treatment
and 20 000 became blind or severely sight
impaired.2 Two-thirds of children suffering
sight loss from ROP live in middle-income
and moderately developed countries, particu-
larly Latin America.1 2 Incidence of blindness
from ROP is lower in highly developed coun-
tries (3–13%), where risk factors such as
oxygen supplementation and blood oxygen
saturation are monitored meticulously, and
minimal in poorly developed countries,
where premature babies often do not
survive.1 In highly and moderately developed
countries, the incidence of ROP is increas-
ing, as advances in neonatal management
allow more premature infants to survive
despite very low gestational age and birth
weight.3 4
The current standard treatment for sight-
threatening ROP is laser photoablation of
the non-vascularised, immature retina.
Treatment decisions are based on severity
(stage 1–5 or an aggressive posterior form of
Strengths and limitations of this study
▪ High case ascertainment using robust epidemio-
logical methodology.
▪ High-quality data, based on individual case
reports from highly qualified specialists in paedi-
atric ophthalmology.
▪ High completion rate of reports.
▪ Case ascertainment relying on practitioners noti-
fying cases possibly led to small degree of
under-reporting, affecting numerator of incidence
estimate.
▪ Epidemiological data for denominator (number of
low-birthweight infants) not available for full area
surveyed and in part extrapolated from reported
data.
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the condition, aggressive posterior ROP (AP-ROP)) and
location (zone 1–3) of the disease and retinal vascular
changes (plus disease) as deﬁned by the International
Committee for the Classiﬁcation of ROP.5 Early treat-
ment is now recommended to avoid progression to sight-
threatening complications; a clinical algorithm advocates
treatment for ‘type 1’ or ‘high-risk prethreshold’ ROP,
deﬁned as ‘zone 1 stage 3 ROP with or without plus, or
zone 1 stage 1/2 with plus, or zone 2 stage 2/3 with plus
disease’.6 However, treatment is occasionally given for
earlier forms of ROP, that is, ‘type 2’ or ‘low-risk pre-
threshold’ ROP (zone 1, stage 1 or 2 without plus, or
zone 2, stage 3 without plus disease)6 and ‘mild ROP’
(milder than type 2).7
However, even with timely laser photocoagulation,
ROP results in unfavourable structural and visual out-
comes in a small, but signiﬁcant number of children.6 8 9
It usually requires intubation and sedation or general
anaesthesia, which may not be safe in systemically
unstable infants, and it irreversibly destroys the periph-
eral retina, reducing the peripheral visual ﬁeld.
Following the successes in the treatment of age-related
macular degeneration (AMD) and diabetic retinopathy,
recombinant antibodies targeted against vascular endo-
thelial growth factor (VEGF), injected into the vitreous
cavity, have recently been used in addition to laser
photoablation and as ﬁrst-line monotherapy to treat the
most severe forms of ROP.10 Neither ranibizumab nor
bevacizumab is licensed for this indication, though rani-
bizumab is licensed for intravitreal injection in AMD
and few other retinal conditions. Despite being
unlicensed,11 bevacizumab is in ophthalmic use, as it
incurs only a fraction of the cost of ranibizumab while
having equivalent efﬁcacy.12
In ROP, reported beneﬁts of VEGF inhibitors include
fast regression of neovascularisation and plus disease,
vascularisation of the peripheral retina and the lack of a
need for general anaesthesia. However, local and sys-
temic safety is unknown. In infants, VEGF is vital in
directing the sequential and orderly development of
blood vessels in the retina and systemically.13 14 After
injection into the eye, these agents enter the systemic
circulation, and there are concerns about dose and
timing of administration and potential adverse events,
ocular and systemic. Most studies reporting the use of
VEGF inhibitors in ROP have used bevacizumab rather
than ranibizumab, partly because the larger size of the
molecule may make it less likely to induce systemic sup-
pression of VEGF serum levels; there are, however, no
pharmacokinetic data to support this concept.
The lack of central registries or databases for the treat-
ment of ROP hampers the collection of information
about current treatment patterns. To evaluate current
practice patterns in the treatment of ROP in the UK, we
set up a 1-year national surveillance project. The main
objectives of this study are to determine the current inci-
dence of ROP requiring treatment and current treat-
ment preferences.
METHODS
We conducted a prospective epidemiological active sur-
veillance study of ROP treatment in the UK.
Study population
The UK ROP screening guideline recommends screen-
ing of infants <1501 g birth weight and <32 weeks gesta-
tional age.15
As denominator, we identiﬁed the number of premature
births with birth weight of <1500 g in the surveyed area
from the Ofﬁce for National Statistics of England and
Wales, http://www.statistics.org.uk. Scotland and Northern
Ireland do not report on birth weight, so we estimated the
number of low-birthweight (LBW) babies in these areas by
assuming that the proportion of live births who were LBW
was the same as that observed in England. The latest avail-
able birth ﬁgures from the Ofﬁce for National Statistics
show that in 2014, there were 661 496 live births in
England and 33 544 in Wales; of these, respectively, 6987
and 322 had a birth weight of <1500 g. The number of live
births in Northern Ireland and Scotland was 24 394 and
56 725, respectively, so assuming a similar proportion of
LBW babies as observed in England, would have resulted
in 258 and 545 babies, respectively. The total number of
live births with birth weight <1500 g would then be 8112.
Inclusion criteria: any baby with ROP treated or
referred to another unit for treatment between 1
December 2013 and 30 November 2014, with treatment
either in the form of laser therapy, cryotherapy, VEGF
inhibitor or vitrectomy/scleral buckling, or a combin-
ation of these treatments.
Exclusion criteria: any infant not fulﬁlling the above
inclusion criteria.
Data collection
Incident cases were identiﬁed through the existing
reporting system set up by the British Ophthalmic
Surveillance Unit (BOSU). From December 2013 to
December 2014, BOSU mailed cards to all consultant
ophthalmologists and associate specialists in the UK once
a month, with an invitation to report new cases of treated
ROP, deﬁned as above. On receipt of case notiﬁcations,
we mailed a standardised case report form (CRF) collect-
ing clinical data to the reporting ophthalmologists. We
also set up an electronic special interest group (SIG),
through which clinicians could inform the research team
directly of new cases and send completed CRFs.
Definition of ROP severity groups
The CRF asked clinicians to specify severity (stage) and
location (zone) of ROP based on the International
Classiﬁcation of ROP (ICROP).5 6 We then categorised
the data into levels of severity as deﬁned in previous pub-
lications6 7 (table 1). However, not all possible scenarios
of zone/stage/plus disease status are covered by these
classiﬁcations. A particular problem is zone 3 disease with
plus and zone 2 stage 1 with plus; we categorised these as
‘type 2 plus disease’, which is an addition to existing
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classiﬁcations. A second problem is that preplus disease
was not yet deﬁned at the time of the ICROP when type 1
and type 2 disease were described.6 As preplus disease is
considered to carry a high risk of progression,16 and as
close monitoring is recommended, we also categorised
cases of preplus disease as ‘type 2 plus’, with the excep-
tion of zone 1 stage 3 disease, which should be treated
regardless of plus disease status and is categorised as type
1 disease (table 1).
Confounders
We reviewed data to exclude duplication of cases arising
from children being transferred between neonatal units
or consultants, and from reports received via BOSU and
via the SIG routes.
Statistical analysis
Data from the CRFs were entered onto an electronic
Red Cap (Research Electronic Data Capture) database.
A random sample of forms were inspected to ensure
data quality. After data lock, data were transferred into
Stata V.13.0 for analysis. Characteristics of infants
requiring ROP treatment were summarised using means
and SDs for approximately Gaussian continuous vari-
ables and medians and IQRs for non-Gaussian continu-
ous variables. Categorical variables are reported as
numbers and proportions.
RESULTS
Participants—numerator: case ascertainment and
inclusion
During the observation period, BOSU recorded a card
return rate of 77.2%. Clinicians notiﬁed BOSU of 270
cases (ﬁgure 1). We asked clinicians to complete CRF
for 268 babies, excluding one who did not meet the
inclusion criteria. To reduce bias from under-reporting,
we set up a UK ROP-SIG. Members share an electronic
mailing list and can report cases of ROP treatment to
the research team electronically; this route led to com-
munication of 165 cases. In total, we received 370 com-
pleted forms. We excluded one, as treated outside the
observation period, and 42 duplicate reports (same
child, reported by different clinicians/units). We
included 327 cases in the analysis.
Table 1 Severity of retinopathy classification
Zone Stage Plus Severity category Reference
AP-ROP 5
1 3 No plus Type 1 6
1 3 Preplus This study
1 3 Plus disease 6
1 2 Plus disease 6
1 1 Plus disease 6
2 3 Plus disease 6
2 2 Plus disease 6
2 1 Plus disease Type 2 plus This study
3 3 Plus disease
3 2 Plus disease
3 1 Plus disease
1 2 Preplus
1 1 Preplus
2 3 Preplus
2 2 Preplus
2 1 Preplus
3 3 Preplus
3 2 Preplus
3 1 Preplus
1 2 No plus Type 2 6
1 1 No plus
2 3 No plus
2 2 No plus Mild 7
2 1 No plus
3 3 No plus 7
3 2 No plus
3 1 No plus 7
4 Partial retinal detachment 5
5 Total retinal detachment 5
AP-ROP, aggressive posterior retinopathy of prematurity.
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Treatment incidence
Based on the above, the incidence of treatment for ROP
during the observation period was 327/8112 or 4%
(95% CI 3.6% to 4.5%).
Patient characteristics
Of the included patients, 57.8% were male (table 2);
69.7% were white, 13.8% Asian, 5.5% black, 5.2% mixed
and 5.8% other; and 72.8% were singletons, 24.5% twins
and 2.1% triplets. Median (IQR) gestational age at birth
was 25 weeks (24.3–26.1), and median (IQR) birth
weight was 706 g (620–821). Median (IQR) age at ﬁrst
ROP treatment was 80 days (71–96).
Indications for treatment
In the following, we report ﬁgures for the right eye;
ﬁgures for the left eye are similar. At ﬁrst treatment, 204
right eyes (62.39%) had type 1 ROP, and 27 (8.26%)
had AP-ROP (table 3). Type 2 plus ROP was present in
74 right eyes (22.63%), and type 2 in 9 (2.75%). Six
(1.83%) had mild ROP. One infant had bilateral, and
two had unilateral retinal detachments at ﬁrst treatment
(table 3).
Primary treatment
In 90.5% of right eyes, the ﬁrst treatment administered
was diode laser photoablation of the avascular retina
(table 4). One eye received cryotherapy and laser com-
bined (0.3%). Twenty-six infants (8%) received bilateral
VEGF inhibitor injections as primary treatment. One
child (0.3%) received laser in one and VEGF inhibitor
injection in the other eye in the same treatment session,
as a vitreous haemorrhage precluded the view of the
retina in one eye. Data were missing for three right
(0.9%) and six left eyes (1.8%).
Figure 1 Case ascertainment,
data collection and analysis flow
chart (modified from CONSORT,
www.consort-statement.org).
Table 2 Demographic, pregnancy and neonatal details of
infants requiring ROP treatment
Number identified
327Gender
Female 138 (42.2%)
Male 189 (57.8%)
Ethnic group
Asian 45 (13.8%)
Black 18 (5.5%)
Mixed 17 (5.2%)
Other 19 (5.8%)
White 228 (69.7%)
Single/multiple birth
Singleton 238 (72.8%)
Twin 80 (24.5%)
Triplet 7 (2.1%)
Other 2 (0.6%)
Birth weight in g, median (IQR) 706 (620–821)
Gestational age at birth in weeks,
median (IQR)
25 (24.3–26.1)
Age at first ROP treatment in days,
median (IQR)
80 (71–96)
ROP, retinopathy of prematurity.
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DISCUSSION
We present the ﬁrst systematic evaluation of ROP requir-
ing treatment and current treatment preferences in the
UK since the introduction of new treatment recommen-
dations and since the ﬁrst, unlicensed, use of VEGF inhi-
bitors for this condition.
The primary objectives of this study were to estimate
the current incidence of ROP requiring treatment in
the UK and physicians’ current preference for treatment
modalities, including their use of VEGF inhibitors. Over
a 12-month period, we identiﬁed 327 premature infants
treated for ROP, of whom 90.5% received the current
standard treatment, diode laser photoablation, and 8%
received VEGF inhibitors. Using epidemiological ﬁgures
of LBW infants in England and Wales and an estimate of
this ﬁgure for Scotland and Northern Ireland, we
calculated that the incidence of ROP treatment in
infants born with birth weight under 1500 g is 4%.
The principal limitation of our study is the case ascer-
tainment methodology, which informs the numerator in
our calculation of treatment incidence. The BOSU
active surveillance system relies on practitioners notifying
a central research ofﬁce of new cases and to complete
CRFs. We sought to maximise case ascertainment by
setting up a UK ROP-SIG to optimise stakeholder
engagement. The BOSU card return rate (response
rate) for the observation period was 77.2%. SIG pro-
vided notiﬁcation of 165 cases. Most but not all of the
cases notiﬁed via the SIG were formally reported by
CRFs. Over the same period, the National Neonatal
Audit Programme (NNAP), to which most neonatal
units in England and Wales contribute, recorded 321
infants receiving treatment for ROP (personal commu-
nication, Daniel Grey, Data Analyst, NNAP). The geo-
graphic area covered by our study included England and
Wales, and Scotland and Northern Ireland. We recorded
292 infants reported by units in England and Wales, 19
from Scotland and 16 from Northern Ireland. There are
two possible explanations for the lower number of treat-
ment cases in England and Wales we observed in com-
parison to NNAP: either our study delivered an
underestimate, or NNAP data are an overestimate.
During our study period, there was a 77.2% response
rate to BOSU. It would seem plausible that cards were
more often returned when babies were observed, but we
have no evidence to support this. It is possible therefore
that cases were omitted. However, our electronic SIG
picked up babies who were not reported via the BOSU
cards, so we believe that this would mitigate any under-
reporting by BOSU. An alternative explanation for the
discrepancy is that data entry onto the NNAP database
by non-ophthalmic staff may erroneously have recorded
ROP screening visits as ROP treatment episodes, leading
to an overestimate of treatment numbers.
As denominator, we selected infants born with a birth
weight of less than 1500 g. ROP screening criteria
include a second item to deﬁne the infant at risk, that is,
birth before 32 weeks gestational age.17 However, ﬁgures
by gestational age are not routinely captured and so our
denominator will have excluded the small number of
babies who are born before 32 weeks but weigh more
than 1500 g. This approach is consistent with other publi-
cations.18 Unfortunately, ﬁgures of infants with LBW are
not reported throughout the area we surveyed, and we
estimated the proportion of LBW infants in Scotland and
Ireland from those reported for England.
Compared with previous reports, our study provides evi-
dence of an increase in the number of infants treated for
ROP in the UK and evidence of a change in treatment
pattern. A previous BOSU study detected 223 preterm
babies with stage 3 ROP over a 16-month period between 1
December 1997 and 31 March 1999 of whom just 59%
were treated—76% of these with laser photocoagulation
and 22% with cryotherapy.19 This study used a mixed
Table 4 Details of primary treatment
First treatment n=327
Right eye
n (% of
327)
Left eye
n (% of
327)
Same
treatment
modality in
both eyes
n (% of 327)
Diode laser 296 (90.5%) 294 (89.9%) 291 (89.0%)
VEGF
inhibitor
injection
26 (8.0%) 26 (8.0%) 26 (8.0%)
Cryotherapy
and laser
1 (0.3%) 0
VEGF
inhibitor
injection plus
laser*
1 (0.3% 1 (0.3%) 0
Missing data 3 (0.9%) 6 (1.8%) 1 (0.3%)
*Infant who received VEGF inhibitor in one eye and laser
treatment in the other in the same treatment session.
VEGF, vascular endothelial growth factor.
Table 3 Severity of retinopathy in right and left eyes on
the day of first treatment
Severity
category
Number of
right eyes
treated
(% of 327)
Number of
left eyes
treated
(% of 327)
Same
severity in
both eyes
(% of 327)
AP-ROP 27 (8.26) 27 (8.26) 27 (8.26)
Type 1 204 (62.39) 202 (61.77) 174 (53.21)
Type 2 plus 74 (22.63) 69 (21.10) 43 (13.56)
Type 2 9 (2.75) 9 (2.75) 6 (1.83)
Mild 6 (1.83) 9 (2.75) 2 (0.61)
Unknown 1 (0.31) 2 (0.61) 0
Partial
retinal
detachment
1 (0.31) 3 (0.92) 1 (0.31)
Total retinal
detachment
0 0 0
AP-ROP, aggressive posterior retinopathy of prematurity.
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methodology which included a parental survey, requiring
individual consent for study participation. The authors sus-
pected that this led to under-reporting of cases, and they
did not present an incidence ﬁgure. A report from a single
centre in Scotland observed that between 1995 and 2004,
5% of premature infants meeting the UK screening criteria
required treatment.20 Two UK-based studies, which used
large national databases of routinely collected data, NNAP
and Hospital Episode Statistics,21 18 reported signiﬁcantly
lower incidences of ROP requiring treatment (1.5–2%)
than our study (4%), probably due to under-reporting, as
ophthalmologists were not involved in data collection.22 23
The strengths of our approach are high case ascertainment
and data completion. Our treatment incidence ﬁgure is
also comparable with reports from other countries, which
report treatment of 1–5% of infants at risk.24–28
An initially surprising ﬁnding was that 27% of eyes
received treatment for ROP milder than type 1 and
AP-ROP, the current treatment threshold.17 6 8 9
However, the overwhelming majority of these had
preplus disease, which we propose to categorise as ‘type
2 plus’ disease: 74 right and 69 left eyes (22.63% and
21.10%, respectively). In fact, previous reports indicate
that 70% of those with preplus disease at 33–34 weeks
gestational age may progress to requiring laser treat-
ment.16 Treatment for disease earlier than type 1 is also
not a phenomenon limited to our setting: a recent
report of practice patterns of US-based ROP experts
found that a substantial proportion of premature
infants, 9.5%, were treated for ROP milder than type 1,
as practitioners were concerned about as vascular drag-
ging, tractional membranes, vitreous haemorrhages or
persistent ROP, all of which are not captured by the
current ICROP classiﬁcation.7 Our study design did not
collect this level of detailed information, but it is clear
that in the UK, practitioners are concerned particularly
about preplus disease, and provide early treatment.
Finally, our study identiﬁed 26 infants who received
VEGF inhibitor injections as primary and only treat-
ment, and one who received combined VEGF inhibitor
and laser treatment. This is the ﬁrst published national
ﬁgure for this new treatment modality; it may inform
the design of future ROP treatment trials. At present,
the medium and longer term safety and efﬁcacy of this
approach, that is, risk of recurrence of ROP and effects
on cognitive and physical development, are not known,
although concerns about neurodevelopmental outcomes
and late recurrence are emerging.29 30 Some authors
advocate their use for zone 1 ROP or AP-ROP, or in
cases of systemically unwell infants, poor visibility of the
retina, or after failed laser photocoagulation.10 Research
is urgently needed to provide information about safety
and efﬁcacy of these treatments, and to integrate them
into current treatment algorithms.
The treatment incidence we report is likely to be gen-
eralisable to other highly developed countries, where
facilities and staff are available to provide high-intensity
care for infants born prematurely.
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